top of page

Journal: Clinics and Research in Hepatology and Gastroenterology

First author: Rim Bourguiba

Country of study: France and Tunisia

CEREMAIA Tenon author(s): Marion Delplanque, Catherine Grandpeix-Guyodo, Léa Savey, Sophie Georgin-Lavialle

Reference: Bourguiba R, Delplanque M, Grandpeix-Guyodo C, Boursier G, Savey L, Cuisset L, Georgin-Lavialle S. When to suspect monogenic autoinflammatory diseases in patients with digestive symptoms? Clinics and Research in Hepatology and Gastroenterology. 2026;50:102820.

DOI: https://doi.org/10.1016/j.clinre.2026.102820


When to suspect monogenic autoinflammatory diseases in patients with digestive symptoms?

5 key points:

  • Some rare autoinflammatory diseases can cause abdominal pain, diarrhoea, digestive inflammation or symptoms that resemble inflammatory bowel disease.

  • Familial Mediterranean fever is the most common monogenic autoinflammatory disease and should be considered in people of Mediterranean origin with repeated inflammatory abdominal pain.

  • Associated signs such as recurrent fever, mouth ulcers, skin rashes, joint pain, macrocytic anaemia or family history should raise suspicion of an autoinflammatory cause.

  • Diagnosis is based on clinical assessment, inflammation markers, sometimes IL-18 measurement, and appropriate genetic testing.

  • Earlier diagnosis can reduce diagnostic delay, guide treatment and help prevent complications such as AA amyloidosis.


Introduction

Systemic autoinflammatory diseases are rare conditions caused by abnormal activation of the innate immune system, the body’s first line of defence. They can cause flares of inflammation with fever, pain, skin involvement, joint symptoms or digestive problems. In some patients, digestive symptoms are the main feature and may look like inflammatory bowel disease, such as Crohn’s disease.


Methods

This article is a narrative review of the medical literature. The authors describe the main monogenic autoinflammatory diseases that may cause digestive symptoms and highlight situations in which gastroenterologists should consider these diagnoses.


Results

Several diseases can cause abdominal pain, diarrhoea, colitis, digestive ulcers or inflammation that resembles Crohn’s disease. Familial Mediterranean fever is the most common, especially in people of Mediterranean origin. Other conditions include TRAPS, Mevalonate kinase deficiency, cryopyrin-associated diseases, VEXAS syndrome, A20 haploinsufficiency, and diseases linked to RIPK1, RELA, NFKB1, JAK1, STAT, PSTPIP1, ADA2, LACC1, XIAP or PLCG2. Warning signs include recurrent fever, unexplained inflammation in blood tests, mouth ulcers, skin rashes, joint pain, family history, Mediterranean origin, macrocytic anaemia or poor response to usual treatments for inflammatory digestive diseases.


Discussion

The article emphasizes that not all digestive inflammation should automatically be considered a typical bowel disease. An autoinflammatory disease may mimic inflammatory bowel disease, coexist with it, or be revealed by unusual digestive symptoms. Useful investigations may include inflammation markers, endoscopy, specific biomarkers such as IL-18, and above all appropriate genetic testing, ideally discussed with expert centres.


Conclusion

Rare autoinflammatory diseases should be considered when digestive symptoms are inflammatory, unexplained, recurrent or resistant to usual treatments. Early diagnosis can lead to more appropriate care, often using treatments that target inflammation, and may help prevent complications such as AA amyloidosis.


 
 
 
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

First author: Saubia Fathima

Journal: American Journal of Hematology, 2026

Authors of the abstract: Pr Sophie Georgin-Lavialle et Pr Olivier Kosmider


Key points

- In this multicenter cohort of 66 patients with VEXAS syndrome, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was associated with better overall survival than hypomethylating agents (HMAs).

- Allo-HSCT achieved molecular remission in all evaluable patients, compared with 22% under HMAs.

- Corticosteroid withdrawal was markedly more frequent after transplantation than with HMAs.

- HMAs -mainly azacitidine- remained active in some patients, but with a high rate of discontinuation due to toxicity or lack of efficacy.

- These findings support allo-HSCT as a potentially curative strategy in selected patients.


Summary

VEXAS syndrome is an acquired hematoinflammatory disease caused by somatic mutations in the UBA1 gene, affecting mainly men over 50 years of age. It combines systemic autoinflammatory manifestations, cytopenias, and sometimes an associated myelodysplastic syndrome. Management remains challenging, with frequent corticosteroid dependence and often limited effectiveness of steroid-sparing treatments. In this context, this retrospective multicenter U.S. study compared outcomes of two approaches targeting the pathological clone: hypomethylating agents and allogeneic hematopoietic stem cell transplantation.


Sixty-six patients with confirmed VEXAS were included between 2019 and 2025, including 31 treated with allo-HSCT and 35 with an HMA, mainly azacitidine. Indications for therapy were glucocorticoid-refractory inflammation, progressive bone marrow failure or associated myeloid neoplasia, or combinations of these manifestations. The two groups were broadly comparable clinically and biologically, except for older age in the HMA group.


After a median follow-up of 18 months, 14 deaths were observed 3 in the transplant group and 11 in the HMA group. Allo-HSCT was associated with a significant improvement in overall survival, with median survival not reached versus 29.6 months with HMAs, including after adjustment for age and comorbidities. This superiority persisted across several sensitivity analyses, strengthening the robustness of the signal despite methodological limitations inherent to the retrospective design.


Beyond survival, allo-HSCT was associated with major clinical and biological benefit. All evaluable patients achieved molecular remission, with no re-emergence of the UBA1 clone at last follow-up. Corticosteroid discontinuation was also far more frequent after transplantation, with steroid cessation in 58% of patients, versus only 6% with HMAs. By contrast, HMAs showed real but more modest activity, with molecular remission in 22% of evaluable patients and a high treatment discontinuation rate. Nearly one in two patients stopped treatment, mainly due to infections, prolonged cytopenias, toxicity, or lack of response.


Overall, this North American study suggests that allo-HSCT is currently, as expected, the most effective and potentially curative option for eligible patients with VEXAS, particularly in severe disease, steroid dependence, or bone marrow involvement. HMAs may still have a role in patients not immediately eligible for transplant, as bridging therapy or a step toward transplantation, but in this study their benefit appeared more modest and less durable.

 
 
 

Une maladie auto-inflammatoire rare


Dans cet article, le Journal des Femmes Santé examine les causes, les symptômes et la gestion de cette maladie, avec des éclaircissements du Professeur Sophie Georgin-Lavialle, interniste à l'hôpital Tenon.


Syndrome VEXAS : l’essentiel à retenir

Le syndrome VEXAS est une maladie inflammatoire rare, décrite pour la première fois en 2020. Son nom est un acronyme qui signifie Vacuoles, enzyme E1 (UBA1), liée à l'X, auto-inflammatoire, somatique. Cette maladie est causée par une mutation acquise (somatique) du gène UBA1, situé sur le chromosome X. Cette mutation entraîne une inflammation chronique excessive dans tout le corps.


Qui est touché par le syndrome VEXAS ?


Cette maladie touche principalement les hommes de plus de 50 ans. Étant donné que les mutations ne sont pas présentes à la naissance, les symptômes apparaissent à l'âge adulte. Le plus jeune patient décrit avait 46 ans.


Symptômes courants


Les symptômes du syndrome VEXAS incluent :


  • Anémie

  • Fièvre persistante

  • Fatigue sévère

  • Douleurs dans les grandes articulations

  • Lésions cutanées

  • Perte de poids et perte d'appétit

  • Inflammation du cartilage (oreilles, nez – chondrite)

  • Possible atteinte pulmonaire

  • Marqueurs inflammatoires fortement élevés (CRP)


Diagnostic et gestion


Le diagnostic repose sur le séquençage génétique. Cela a permis d'identifier de nombreux patients qui avaient été précédemment mal diagnostiqués avec d'autres maladies inflammatoires ou hématologiques.


Il n'existe pas de phase aiguë typique : l'inflammation est continue, parfois accompagnée de poussées.


Pourquoi certaines personnes développent-elles cette mutation ?


Le syndrome VEXAS reste mal compris, en particulier en ce qui concerne les raisons pour lesquelles certaines personnes développent cette mutation tandis que d'autres ne le font pas.


Conclusion


La recherche continue d'évoluer pour mieux comprendre cette maladie complexe. Il est essentiel de sensibiliser davantage à cette condition afin d'améliorer la prise en charge des patients. Pour en savoir plus sur le syndrome VEXAS, vous pouvez consulter cet article sur Journal des Femmes Santé.


Le Centre de Référence des Maladies Auto-Inflammatoires et de l’Amylose de Tenon (CEREMAIA-Tenon) s'engage à être le leader national dans la prise en charge experte, la recherche et l'éducation pour les maladies auto-inflammatoires rares et l'amylose. Cela vise à améliorer la vie des patients adultes.

 
 
 
bottom of page